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and Anton V. Dolzhenko *ac
Two complementary pathways for the preparation of N-substituted 3-(5-amino-1H-1,2,4-triazol-3-yl)
propanamides (5) were proposed and successfully realized in the synthesis of 20 representative examples.
These methods use the same types of starting materials viz. succinic anhydride, aminoguanidine
hydrochloride, and a variety of amines. The choice of the pathway and sequence of the introduction of
reagents to the reaction depended on the amine nucleophilicity. The ﬁrst pathway started with the
preparation of N-guanidinosuccinimide, which then reacted with amines under microwave irradiation to
aﬀord 5. The desired products were successfully obtained in the reaction with aliphatic amines (primary and
secondary) via a nucleophilic opening of the succinimide ring and the subsequent recyclization of the 1,2,4-
triazole ring. This approach however failed when less nucleophilic aromatic amines were used. Therefore, an
alternative pathway, with the initial preparation of N-arylsuccinimides and their subsequent reaction with
aminoguanidine hydrochloride under microwave irradiation, was applied. The annular prototropic
tautomerism in the prepared 1,2,4-triazoles 5 was studied using NMR spectroscopy and X-ray crystallography.Introduction
1,2,4-Triazoles attract considerable attention in organic and
medicinal chemistry due to their wide spectrum of pharmacolog-
ical activities.1 They have been reported to possess antiviral,2 anti-
bacterial,3 antifungal,4 anticancer,5 and anticonvulsant6 properties.
Among the 1,2,4-triazoles, 3(5)-amino-1,2,4-triazoles were recently
reported to be potent inhibitors of kinases,7 lysine-specic deme-
thylase 1,8 and acidic mammalian chitinase.9 Additionally, 3(5)-
amino-1,2,4-triazoles are also known as important building blocks
for the construction of bioactive triazole-fused heterocycles.10
Due to practical signicance of 3(5)-amino-1,2,4-triazoles,
there is an ongoing demand for new eﬃcient methods of their
synthesis. The most common synthetic methods for the prepa-
ration of 3(5)-amino-1,2,4-triazoles involve intramolecular cyclo-
condensation of amidoguanidines,11 thermal condensation of N-
cyanoimidates with hydrazine,12 and 1,3-dipolar cycloaddition of
hydrazonoyl derivatives and carbodiimides.13 However, thealaysia, Jalan Lagoon Selatan, Bandar
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hemistry 2018existing approaches suﬀer from several drawbacks, including
multi-step preparation process, harsh reaction conditions, poor
selectivity of reactions and tedious purication procedures.
Over the past decade, there has been a substantial increase
in the application of microwave irradiation in organic synthesis.
It is a valuable tool used for improving the outcome of reac-
tions, oen resulting in higher yield and product purity.14
Utilization of microwave irradiation for the synthesis of 1,2,4-
triazoles has shown to provide practical and economical
advantages.11e,15 Herein, we report the development of eﬃcient
microwave-assisted methods for the preparation of 3-(5-amino-
1H-1,2,4-triazol-3-yl)propanamides (5).
Annular prototropic tautomerism is an interesting phenom-
enon oen observed in compounds possessing a 1,2,4-triazole
ring in their structure. The tautomeric preferences and factors
aﬀecting equilibrium between tautomers have been studied
theoretically and experimentally, thermodynamically and kineti-
cally due to their importance in determining chemical and bio-
logical properties of compounds.16 We applied NMR spectroscopy
to explore tautomerism in the prepared compounds and report
here our ndings. X-ray crystallography was used to determine
a position of the triazole ring hydrogen in the solid state.Results & discussion
Synthesis of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanamides (5)
from N-guanidinosuccinimide (2)
Our initial synthesis design involved the preparation of 3-(5-
amino-1H-1,2,4-triazol-3-yl)propanamides (5) from N-RSC Adv., 2018, 8, 22351–22360 | 22351
Scheme 1 Two pathways to the synthesis of N-substituted 3-(5-amino-1H-1,2,4-triazol-3-yl)propanamides (5).
Table 1 Optimization of conditions for the synthesis of N-morpho-
lino-substituted 3-(5-amino-1H-1,2,4-triazol-3-yl)propanamide (5a)a
Entry Solvent Temperature (C) Time (min) Isolated yield (%)
1 EtOH 180 25 27
2 H2O 180 25 28
3 AcOEt 180 25 64
4 MeCN 180 25 75
5 MeCN 170 25 79
6 MeCN 160 25 65
7 MeCN 170 30 73
8 MeCN 170 20 73
9b MeCN 170 25 68
10c MeCN 170 25 66
a The reaction was performed using Discover SP CEM microwave
synthesizer with 1 mmol of 2 and 2 mmol of morpholine in 1 mL of
the specied solvent. b 1 mmol of 2 and 3 mmol of morpholine were
used for the reaction. c 1 mmol of 2 and 1.5 mmol of morpholine
were used for the reaction.
RSC Advances Paperguanidinosuccinimide (2) using nucleophilic ring opening of
the latter with amines followed by the cyclocondensation of
intermediates 3 and closure of the 1,2,4-triazole ring (Scheme 1,
Pathway A). We also proposed that performing the process
under high temperature using microwave irradiation would be
eﬃcient to have a tandem of these reactions happened in the
one-pot fashion.
In the model reaction, N-guanidinosuccinimide (2),
prepared from succinic anhydride (1) according to the reported
method,11c was treated with morpholine under microwave irra-
diation to give 3-(5-amino-1H-1,2,4-triazol-3-yl)propanamide 5a
(Table 1). The optimization of conditions for the synthesis of 5a
started with an attempt to perform the reaction of 2 with mor-
pholine in ethanol under microwave irradiation at 180 C for
25 min (Table 1, Entry 1). To our satisfaction, we successfully
obtained the desired product 5a in high purity aer simple22352 | RSC Adv., 2018, 8, 22351–22360ltration; however the yield was rather low (27%). The screening
of solvents revealed that conducting the reaction in acetonitrile
led to a better yield (Entry 4). Further optimising of the reaction
conditions, we found that decreasing the reaction temperature
to 170 C led to yield improvements (Entry 5). Therefore, the
satisfactory results were achieved when the synthesis of N-
morpholino-substituted 3-(5-amino-1H-1,2,4-triazol-3-yl)
propanamide (5a) was performed using reaction of 2 with
morpholine in acetonitrile at 170 C for 25 minutes.
The optimized conditions for the preparation of 5a were
successfully applied for the synthesis of 5b–i allowing the
preparation of a diverse library of substituted amides of 3-(5-
amino-1H-1,2,4-triazol-3-yl)propanoic acid (5a–i) in the 1 mmol
scale (Table 2). Using these optimized conditions, we attempted
to scale up the reaction from 1 mmol to 10 mmol. The synthesis
of some products (5a, 5b, 5d, and 5i) was performed in the
10 mmol scale with similar results.
However, when we attempted to further extend the reaction
scope and involve aniline in the reaction with N-guanidino-
succinimide (2) under the optimized conditions, only starting
material 2 was isolated. The analysis of the reaction mixture in
the attempt to prepare 5j from 2 revealed the presence of aniline
and unreacted 2 only. We propose that the nucleophilicity of
aniline was not suﬃcient to initiate the ring opening of the
cyclic imide and undergo the cascade of transformations.Synthesis of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanamides (5)
via N-arylsuccinimides (4)
To overcome this problem limiting themethod scope, we designed
an alternative pathway for the preparation of N-phenyl-substituted
3-(5-amino-1H-1,2,4-triazol-3-yl)propanamide (5j) via the reaction
of N-phenylsuccinimide (4a) with aminoguanidine hydrochloride
(Scheme 1, Pathway B). Aminoguanidine, beingmore nucleophilic,
should be able to initiate the imide ring opening. Moreover, the
guanidinium ion also might act as an acid catalyst increasing
electrophilicity of the imide carbonyl group in this reaction. The
neutralisation of the guanidinium ion on the intermediate in the
second step supposed to facilitate the 1,2,4-triazole ring formation.
We attempted to carry out both steps in a one-pot fashion
under microwave irradiation. First, N-phenylsuccinimide (4a) was
heated with aminoguanidine hydrochloride in ethanol at 170 CThis journal is © The Royal Society of Chemistry 2018
Table 2 Microwave-assisted synthesis of substituted amides of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanoic acid (5a–j)a
a The reactions were performed using a Discover SP CEM microwave synthesizer at 170 C for 25 min with 1 mmol of N-guanidinosuccinimide (2)
and 2 mmol of amine in 1 mL of acetonitrile. b The reactions were scaled up to 10 mmol of N-guanidinosuccinimide (2) and 20 mmol of amine in
10 mL of acetonitrile.
Paper RSC Advancesfor 50 min. Aer cooling, an aqueous solution of potassium
hydroxide was added to the reaction mixture and heating was
continued at 180 C for 15 min. We found that using non-aqueous
solution of the same base dramatically increased the yield, while
altering the solvent of the reaction had minimal eﬀect on the
outcome of the reaction (Table 3, Entries 2–5). Continuing opti-
mization of the process using ethanol as the solvent, we observed
that altering the reaction time before and aer the addition of the
base did not improve the outcome of the reaction (Entries 6–8).
Unfortunately, further manipulations with the reaction tempera-
ture, time, type of base, or ratio of the reagents did not lead to any
improvement in yields (e.g. Entries 9–11). These conditions were
the most eﬃcient for the preparation of 3-(5-amino-1H-1,2,4-
triazol-3-yl)propananilide (5j), which was obtained using this one-
pot process in 58% yield (Entry 3).
To explore the scope of this new method for the synthesis of
other arylamides of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanoic
acid, we prepared a library of N-arylsuccinimides (4) from suc-
cinic anhydride (1) and anilines adopting the approach reported
by Benjamin et al. (Scheme 2).17 However, this method failed
when applied to ortho- and meta-substituted anilines and
therefore imides 4c, 4d, 4f, and 4i were synthesized via inter-
mediate N-arylsuccinamic acids (6).18 The N-arylsuccinimides
(4) were then used as substrates in the reaction with amino-
guanidine hydrochloride to prepareN-arylamides of 3-(5-amino-This journal is © The Royal Society of Chemistry 20181H-1,2,4-triazol-3-yl)propanoic acid (5j–t) using the optimised
conditions (Table 4). A wide range of substituents in various
positions of the benzene ring of 4 were equally well tolerated in
the reaction with aminoguanidine hydrochloride. In all cases,
N-arylamides of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanoic acid
(5j–t) were isolated in high purity via simple ltration. The
reaction was eﬀectively performed in both 1 and 10mmol scales
with similar outcomes.Annular prototropic tautomerisation of 3-(5-amino-1H-1,2,4-
triazol-3-yl)propanamides (5) in solution
Due to annular prototropic tautomerism, the prepared 5(3)-
amino-1,2,4-triazoles may exist in three forms: 5-amino-1H-
1,2,4-triazoles 5, 3-amino-1H-1,2,4-triazoles 50, and 5-amino-4H-
1,2,4-triazoles 500 (Scheme 3). We attempted to analyse tauto-
meric equilibria in the prepared triazoles using NMR
spectroscopy.
In the 13C NMR spectra of the prepared compounds, the
triazole ring signals appeared as two broad signals conrming
its involvement in tautomerism. However, the tautomeric
transformations were probably too fast to be detected by the 13C
NMR spectroscopy under the experimental conditions and
therefore tautomers were indistinguishable.
For majority of the N-alkyl-3-(5(3)-amino-1,2,4-triazol-3(5)-yl)
propanamides (5a–5f and 5i), the separate signals of individualRSC Adv., 2018, 8, 22351–22360 | 22353
Table 3 Optimization of conditions for the synthesis of 3-(5-amino-1H-1,2,4-triazol-3-yl)propananilide (5j)a
Entry
Conditions
Isolated yield (%)(i) (ii)
1 170 C, 50 min, EtOH 180 C, 15 min, KOH in H2O 23
2 170 C, 50 min, MeOH 180 C, 15 min, KOH in MeOH 54
3 170 C, 50 min, EtOH 180 C, 15 min, KOH in EtOH 58
4 170 C, 50 min, iPrOH 180 C, 15 min, KOH in iPrOH 51
5 170 C, 50 min, MeCN 180 C, 15 min, KOH in EtOH 44
6 170 C, 40 min, EtOH 180 C, 15 min, KOH in EtOH 56
7 170 C, 60 min, EtOH 180 C, 15 min, KOH in EtOH 57
8 170 C, 50 min, EtOH 180 C, 20 min, KOH in EtOH 51
9 170 C, 50 min, EtOH 170 C, 30 min, KOH in EtOH 48
10 170 C, 50 min, EtOH 180 C, 15 min, NaOH in EtOH 55
11b 170 C, 50 min, EtOH 180 C, 15 min, KOH in EtOH 55
a The reactions were performed using a Discover SP CEM microwave synthesizer with 1 mmol of 4a and 1 mmol of aminoguanidine hydrochloride
in 1 mL of the specied solvent in the rst step and addition of 1.2 mmol of the base in the second step. b 1.2 mmol of aminoguanidine
hydrochloride and 1.4 mmol of KOH were used in the reaction.
Scheme 2 Synthesis of N-arylsuccinimides (4).
RSC Advances Papertautomers were not identiable in their 1H NMR spectra.
Nevertheless, 1H NMR spectra of some products gave two sets of
signals for the primary amino group and the triazole proton.
Using literature data,11e,16 these signals were attributed to
tautomers 5 and 50. The indicated signals were resolved in the
spectra of compounds possessing at the amide group N-
substituent with relatively higher electronegativity, i.e. anilides
5j–5t and two N-benzylamides with 3,4-diuoro- (5g) and 3-tri-
uoromethyl (5h) substituents. For these compounds (5g, 5h,
5j–5t), equilibrium constant (KT) and corresponding Gibbs free
energy (DG300) values were estimated (Table 5). In the equilibria
for these compounds, 5-amino-1H-1,2,4-triazoles 5, were found
to be the predominant tautomers. Similarly to the earlier re-
ported data,11e,16b the higher the electron-withdrawing proper-
ties of a substituent at the carbon atom the triazole ring, the
more equilibria were shied towards 5-amino-1H-tautomers 5.X-ray crystallography
The tautomerizable 1,2,4-triazoles with a primary amino on
a carbon atom typically crystallize as 5-amino-forms with an
annular hydrogen atom located at the side of the amino group.1922354 | RSC Adv., 2018, 8, 22351–22360An example of two tautomers (5-amino- and 3-amino-forms) of
1H-1,2,4-triazoles appearing together in one crystal was also
reported.20 To explore tautomeric preferences in the prepared
compounds in solid state, the crystal and molecular structures
of a representative compound 5j were determined by X-ray
crystallography; the molecular structure is shown in Fig. 1.
The key point of interest in the structure determination is the
assignment of the tautomeric form for the triazole ring. The
crystallographic analysis indicates the ring-H atom to be located
on the N1 atom of the 5-amino-form (see Experimental). This
assignment, i.e. 5-amino-1H-1,2,4-triazole, is conrmed in the
distribution of bond lengths within the ring and in the nature of
the supramolecular association in the crystal of 5j (see below).
Thus, the C5–N1 bond length of 1.3359(15) A˚ is considerably
longer than the C3–N2 bond of 1.3164(15) A˚; the N1–N2 bond
length is 1.3837(14) A˚. Further, the C3–N4 and C5–N4 bond
lengths vary systematically, i.e. 1.3681(15) A˚ is longer than
1.3351(15) A˚. These observations are consistent with local-
isation of p-electron density in the C3–N2 and C5–N4 bonds.
Overall, the molecule has the shape of the letter L as seen in the
values of the dihedral angles formed between the central amide
residue (r.m.s. deviation of the O8, N8, C7 and C8 atoms from
the least-squares plane ¼ 0.0084 A˚) and the ve- and six-
membered rings of 79.54(4) and 24.78(6), respectively, indi-
cating, to a rst approximation, a co-planar relationship
between the amide and phenyl groups with the triazole ring
lying perpendicular to this; the dihedral angle between the ve-
and six-membered rings is 86.65(4).
As mentioned above, the molecular packing in the crystal of
5j conrms the assignment of the tautomeric form of the ve-
membered ring. The crucial hydrogen bonding involving theThis journal is © The Royal Society of Chemistry 2018
Table 4 Microwave-assisted synthesis of N-arylamides of 3-(5-amino-1H-1,2,4-triazol-3-yl)propanoic acid (5j–t)a
Compound Structure Scale (mmol) Yield (%) Melting point (C)
5j
1 58
245–246b10 56
5k
1 56
218–220c10 61
5l
1 42
179–181d10 60
5m
1 64
209–210d10 74
5n
1 64
219–220c10 67
5o
1 46
202–203d10 47
5p
1 48
221c10 43
5q
1 59
187–188d10 68
5r
1 26
174–175d10 31
5s
1 50
221–222c10 46
5t
1 38
267–269b10 44
a The reaction was performed using a Discover SP CEM microwave synthesizer at 170 C for 50 min in EtOH followed by the addition of KOH in
EtOH and heating at 180 C for 15 min. b Recrystallisation solvent: H2O.
c Recrystallisation solvent: MeOH. d Recrystallisation solvent: MeCN.
Scheme 3 Theoretically possible annular tautomerism in 3-(5(3)-
amino-1,2,4-triazol-3(5)-yl)propanamides.
This journal is © The Royal Society of Chemistry 2018
Paper RSC Advancestriazole ring sees the formation of donor triazole-N1–H/O8
(carbonyl) and acceptor amine-N5–H/N2 (triazole) hydrogen
bonds conrming protonation at the triazole-N1 atom at the
amino group side. The second amine-N5–H atom forms
a comparatively weaker hydrogen bond to the carbonyl-O8 atom
to close a seven-membered {NH/O/HNH/N} supramolec-
ular synthon; geometric details of the hydrogen bonding are
given in the caption to ESI Fig. S1.† As shown in Fig. 2, three
molecules are involved in the aforementioned hydrogen
bonding scheme so that the seven-membered synthon is
anked on either side by 11-membered {NH/OC4N/HNC}
synthons. Connections between the aforementioned aggregatesRSC Adv., 2018, 8, 22351–22360 | 22355
Table 5 Tautomeric composition of 3-(5(3)-amino-1H-1,2,4-triazol-
3(5)-yl)propanamidesa
Compounds
Signals of tautomers in 1H
NMR spectra (ppm)
KT DG300 (kJ mol1)
NH2 NH (triazole)
5 50 5 50
5g 5.76 5.07 11.58 12.30 3.0 2.7
5h 5.74 5.11 11.60 12.30 3.0 2.7
5j 5.77 5.04 11.57 12.32 3.2 2.9
5k 5.77 5.00 11.57 12.33 3.2 2.9
5l 5.81 5.00 11.60 12.34 3.3 3.0
5m 5.78 4.99 11.56 12.33 3.5 3.2
5n 5.78 4.98 11.56 12.32 3.3 3.0
5o 5.77 4.98 11.56 12.32 3.2 2.9
5p 5.77 5.03 11.56 12.31 3.0 2.7
5q 5.78 4.98 11.56 12.32 3.2 2.9
5r 5.76 5.07 11.58 12.30 3.3 3.0
5s 5.77 4.98 11.55 12.31 3.0 2.7
5t 5.77 4.97 11.55 12.32 3.2 2.9
a The NMR spectroscopy was performed at 27 C (300 K) using DMSO-d6
as a solvent.
Fig. 1 Molecular structure of 5j showing atom labelling scheme and
70% anisotropic displacement parameters.
Fig. 2 Hydrogen bonding between four molecules in the crystal of 5j.
The N–H/O and N–H/N hydrogen bonding (see ESI Fig. S1†), are
shown as orange and blue dashed lines, respectively. Non-partici-
pating hydrogen atoms have been omitted.
22356 | RSC Adv., 2018, 8, 22351–22360
RSC Advances Paperare of the type amide-N8–H/N4 (triazole) which generate
centrosymmetric, 14-membered {/NC4NH}2 synthons. The
hydrogen scheme just described extends laterally to form
a supramolecular layer parallel to (1 0 1), see ESI Fig. S1a.† The
most obvious directional points of contact between layers to
consolidate the three-dimensional molecular packing are of the
type methylene-C7–H/p(C9–C14); a view of the unit cell
contents is shown in ESI Fig. S1b.†Conclusion
In conclusion, we developed two complementing each other
pathways for the synthesis of 3-(5-amino-1H-1,2,4-triazol-3-yl)
propanamides (5) under microwave irradiation. Our methods
were successfully applied for the preparation of a diverse library
of twenty N-substituted 3-(5-amino-1H-1,2,4-triazol-3-yl)
propanamides (5) in 1 and 10 mmol scales. Their tautomeric
preferences were analysed using NMR spectroscopy and X-ray
crystallography.Experimental section
General information
Melting points (uncorrected) were determined on a Stuart™
SMP40 automatic melting point apparatus. 1H and 13C NMR
spectra were recorded on a Bruker Fourier 300 spectrometer
(300 MHz), using DMSO-d6 as a solvent and TMS as an internal
reference. IR spectra were recorded on a Varian 640-IR FT-IR
spectrometer using KBr mode. Microwave-assisted reactions
were performed in closed vessel focused single mode using
a CEM Discover SP microwave synthesizer (CEM, USA). The
reaction temperatures were measured by an equipped IR
sensor.General method for the microwave-assisted synthesis of 3-(5-
amino-1H-1,2,4-triazol-3-yl)propanamides (5a-b, and 5d–i)
A mixture of N-guanidinosuccinimide (2) (156 mg, 1 mmol) and
specied amine (2 mmol) in acetonitrile (1 mL) were irradiated
in 10 mL seamless pressure vial using microwave system oper-
ating at maximal microwave power up to 300 W at 170 C for
25 min. Aer cooling, the precipitated product was ltered,
washed with acetonitrile and recrystalised from a suitable
solvent. The reaction was also replicated in an increase scale of
N-guanidinosuccinimide (2) (1.56 g, 10 mmol) and specied
amine (20 mmol) in acetonitrile (10 mL).
3-(5-Amino-1H-1,2,4-triazol-3-yl)-1-morpholinopropan-1-one
(5a). Yellowish solid, yield (1 mmol/10 mmol scale): 178 mg
(79%)/1.97 g (88%), mp 166–167 C (MeCN). 1H NMR (300 MHz,
DMSO-d6): d 2.65 (4H, br s, (CH2)2C]O), 3.41–3.44 (2H, m,
(CH2)N), 3.53–3.54 (2H, m, (CH2)O), 5.58 (2H, br s, NH2), 11.79
(1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.1
(CH2CH2C]O), 30.1 (CH2CH2C]O), 41.4 (CH2N), 45.2 (CH2N),
65.98 ((CH2)2O), 158.2–158.6 (C-3 and C-5), 170.0 (C]O). IR
(KBr) n 3331 (N–H), 3192 (N–H), 1619 (C]O), 1542, 1476, 1255,
1115, 1064, 1013 cm1. Anal. calcd for C9H15N5O2: C, 47.99; H,
6.71; N, 31.09. Found: C, 47.85; H, 6.77; N, 30.97.This journal is © The Royal Society of Chemistry 2018
Paper RSC Advances3-(5-Amino-1H-1,2,4-triazol-3-yl)-1-(piperidin-1-yl)propan-1-one
(5b). White solid, yield (1 mmol/10 mmol scale): 180 mg (81%)/
1.62 g (73%), mp 165–167 C (MeCN). 1H NMR (300 MHz, DMSO-
d6): d 1.42–1.60 (6H, m, (CH2)3), 2.62 (4H, s, (CH2)2C]O), 3.36–
3.42 (4H, m, (CH2)2N), 5.53 (2H, br s, NH2), 11.69 (1H, br s, NH).
13C NMR (75 MHz, DMSO-d6): d 23.2 (CH2CH2C]O), 24.0 (CH2),
25.2 (CH2), 25.9 (CH2), 30.4 (CH2CH2C]O), 41.9 (CH2N), 45.7
(CH2N), 158.5 (C-3 and C-5), 169.2 (C]O). IR (KBr) n 3305 (N–H),
3138 (N–H), 1617 (C]O), 1479, 1405, 1287, 1135, 1098,
1067 cm1. Anal. calcd for C10H17N5O: C, 53.79; H, 7.67; N, 31.37.
Found: C, 53.67; H, 7.72; N, 31.24.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-benzyl)propanamide (5d).
White solid, yield (1 mmol/10 mmol scale): 191 mg (78%)/2.05 g
(84%), mp 208–210 C (EtOH). 1H NMR (300 MHz, DMSO-d6):
d 2.45–2.49 (2H, m, CH2CH2C]O), 2.67 (2H, t,
3J ¼ 7.7 Hz,
CH2CH2C]O), 4.26 (2H, d,
3J ¼ 5.9 Hz, CH2NH), 5.61 (2H, br s,
NH2), 7.21–7.33 (5H,m, H-20, H-30, H-40, H-50andH-60), 8.35 (1H, br
t, 3J ¼ 5.6 Hz, NHC]O), 11.67 (1H, br s, NH). 13C NMR (75 MHz,
DMSO-d6): d 23.6 (CH2CH2C]O), 33.4 (CH2CH2C]O), 41.9
(CH2NH), 126.5 (C-40), 127.0 (C-20 and C-60), 128.1 (C-30 and C-50),
139.5 (C-10), 158.3 (C-3 and C-5), 171.2 (C]O). IR (KBr) n 3414 (N–
H), 3324 (N–H), 3247 (N–H), 1638 (C]O), 1546, 1482, 1225, 1081,
1058, 1003 cm1. Anal. calcd for C12H15N5O: C, 58.76; H, 6.16; N,
28.55. Found: C, 58.61; H, 6.30; N, 28.47.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-methoxybenzyl)prop-
anamide (5e). White solid, yield: 224 mg (84%), mp 218–
220 C (EtOH). 1H NMR (300 MHz, DMSO-d6): d 2.38–2.48 (2H,
m, CH2CH2C]O), 2.65 (2H, t,
3J ¼ 7.7 Hz, CH2CH2C]O), 3.72
(3H, s, OCH3), 4.19 (2H, d,
3J ¼ 5.9 Hz, CH2NH), 5.62 (2H, br s,
NH2), 6.87 (2H, d,
3J ¼ 8.7 Hz, H-30 and H-50), 7.15 (2H, d, 3J ¼
8.7 Hz, H-20 and H-60), 8.27 (1H, br t, 3J ¼ 5.7 Hz, NHC]O),
11.64 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.6
(CH2CH2C]O), 33.4 (CH2CH2C]O), 41.3 (CH2NH), 54.9
(OCH3), 113.6 (C-30 and C-50), 128.3 (C-20 and C-60), 131.4 (C-10),
158.0 (C-40), 159.5 (C-3 and C-5), 171.0 (C]O). IR (KBr) n 3413
(N–H), 3324 (N–H), 3246 (N–H), 1637 (C]O), 1547, 1482, 1257,
1106, 1058, 1032 cm1. Anal. calcd for C13H17N5O2: C, 56.71;
H, 6.22; N, 25.44. Found: C, 56.58; H, 6.31; N, 25.32.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-uorobenzyl)prop-
anamide (5f). White solid, yield: 199 mg (76%), mp 218–219 C
(EtOH). 1H NMR (300 MHz, DMSO-d6): d 2.41–2.51 (2H, m,
CH2CH2C]O), 2.67 (2H, t,
3J¼ 7.6 Hz, CH2CH2C]O), 4.24 (2H,
d, 3J¼ 5.9 Hz, CH2NH), 5.61 (2H, br s, NH2), 7.12 (2H, dd, 3JHH¼
8.9 Hz, 3JHF¼ 8.9 Hz, H-30 and H-50), 7.25 (2H, dd, 4JHF¼ 5.7 Hz,
3JHH ¼ 8.8 Hz, H-20 and H-60), 8.36 (1H, br t, 3J ¼ 5.8 Hz, NHC]
O), 11.69 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.6
(CH2CH2C]O), 33.4 (CH2CH2C]O), 41.2 (CH2NH), 114.8 (d,
2JCF ¼ 21.6 Hz, C-30 and C-50), 128.9 (d, 3JCF ¼ 8.20 Hz, C-20 and
C-60), 135.7 (d, 4JCF ¼ 3.0 Hz, C-10), 157.4 (C-3 and C-5), 161.0 (d,
1JCF ¼ 242.0 Hz, C-40), 171.2 (C]O). IR (KBr) n 3415 (N–H), 3325
(N–H), 3248 (N–H), 1639 (C]O), 1547, 1482, 1225, 1094, 1059,
1005 cm1. Anal. calcd for C12H14FN5O: C, 54.75; H, 5.36; N,
26.60. Found: 54.68; H, 5.40; N, 26.54.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(3,4-diuorobenzyl)prop-
anamide (5g). White solid, yield: 136 mg (48%), mp 173–175 C
(EtOH). 1H NMR (300 MHz, DMSO-d6): d 2.47–2.68 (4H, m,This journal is © The Royal Society of Chemistry 2018CH2CH2C]O), 4.25 (2H, d,
3J ¼ 5.9 Hz, CH2NH), 5.07–5.76 (2H,
br s, NH2), 7.05–7.09 (1H, m, H-20), 7.23–7.40 (2H, m, H-50 and
H-60), 8.42 (1H, br t, 3J¼ 5.6 Hz, NHC]O), 11.58–12.30 (1H, br s,
NH). 13C NMR (75 MHz, DMSO-d6): d 24.0 (CH2CH2C]O), 33.3
(CH2CH2C]O), 41.0 (CH2NH), 115.9 (d,
2JCF ¼ 17.4 Hz, C-20),
117.1 (d, 2JCF ¼ 17.0 Hz, C-50), 123.6 (dd, 4JCF ] 3.1 Hz, 3JCF ¼
7.0 Hz, C-60), 137.5 (dd, 4JCF ¼ 3.8 Hz, 3JCF ¼ 5.5 Hz, C-10), 148.2
(dd, 2JCF ¼ 12.5 Hz, 1JCF ¼ 243.8 Hz, C-40), 149.1 (dd, 2JCF ¼
12.7 Hz, 1JCF ¼ 245.1 Hz, C-30), 156.7 and 159.8 (C-3 and C-5),
171.4 (C]O). IR (KBr) n 3417 (N–H), 3322 (N–H), 3246 (N–H),
1636 (C]O), 1554, 1433, 1226, 1115, 1061, 1014 cm1. Anal.
calcd for C12H13F2N5O: C, 51.24; H, 4.66; N, 24.90. Found: C,
51.09; H, 4.72; N, 24.78.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(3-triuoromethylbenzyl)
propanamide (5h). White solid, yield: 181 mg (58%), mp 157–
158 C (EtOH). 1H NMR (300 MHz, DMSO-d6): d 2.48–2.71 (4H,
m, CH2CH2C]O), 4.36 (2H, d,
3J ¼ 5.9 Hz, CH2NH), 5.11–5.74
(2H, br s, NH2), 7.54–7.59 (4H, m, H-20, H-30, H-50 and H-60), 8.49
(1H, br t, 3J ¼ 5.5 Hz, NHC]O), 11.60–12.30 (1H, br s, NH). 13C
NMR (75 MHz, DMSO-d6): d 23.9 (CH2CH2C]O), 33.4
(CH2CH2C]O), 41.5 (CH2NH), 123.3 (q,
3JCF ¼ 3.7 Hz, C-40),
123.5 (q, 3JCF ¼ 3.8 Hz, C-20), 124.2 (q, 1JCF ¼ 272.2 Hz, CF3),
128.9 (q, 2JCF ¼ 31.4 Hz, C-30), 129.3 (C-50), 131.2 (C-60), 141.1 (C-
10), 156.8 and 159.8 (C-3 and C-5), 171.5 (C]O). IR (KBr) n 3410
(N–H), 3321 (N–H), 3232 (N–H), 1641 (C]O), 1553, 1480, 1260,
1167, 1115, 1071 cm1. Anal. calcd for C13H14F3N5O: C, 49.84;
H, 4.50; N, 22.36. Found: C, 49.79; H, 4.53; N, 22.29.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(phenethyl)propanamide
(5i). White solid, yield (1 mmol/10 mmol scale): 211 mg (81%)/
2.13 g (82%), mp 188–190 C (EtOH). 1H NMR (300 MHz, DMSO-
d6): d 2.37 (2H, t,
3J ¼ 7.9 Hz, CH2CH2C]O), 2.60 (2H, t, 3J ¼
7.8 Hz, CH2CH2C]O), 2.69 (2H, t,
3J¼ 7.4 Hz, CH2CH2NH), 3.25
(2H, q, 3 J ¼ 6.8 Hz, CH2CH2NH), 5.59 (2H, br s, NH2), 7.17–7.31
(5H, m, H-20, H-30, H-40, H-50and H-60), 7.94 (1H, br t, 3J¼ 5.4 Hz,
NHC]O), 11.68 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6):
d 23.6 (CH2CH2C]O), 33.4 (CH2CH2C]O), 35.1 (CH2CH2NH),
40.1 (CH2CH2NH), 125.9 (C-40), 128.2 (C-20 and C-60), 128.5 (C-30
and C-50), 139.4 (C-10), 158.5 (C-3 and C-5), 171.0 (C]O). IR
(KBr) n 3417 (N–H), 3325 (N–H), 3241 (N–H), 1640 (C]O), 1553,
1479, 1227, 1085, 1063, 1018 cm1. Anal. calcd for C14H17N5O:
C, 60.21; H, 6.61; N, 27.01. Found: C, 60.08; H, 6.70; N, 26.88.Microwave-assisted synthesis of 3-(5-amino-1H-1,2,4-triazol-3-
yl)-1-(pyrrolidin-1-yl)propan-1-one (5c)
A mixture of N-guanidinosuccinimide (2) (156 mg, 1 mmol) and
pyrrolidine (165 mL, 2 mmol) in acetonitrile (1 mL) were irra-
diated in 10 mL seamless pressure vial using microwave system
operating at maximal microwave power up to 300 W at 170 C
for 25 min. Aer cooling, the solvent was evaporated under
vacuum and the residue was triturated with ethyl acetate. The
precipitate formed, was ltered, washed with ethyl acetate and
recrystalised from ethanol to give desired product 5c. White
solid; yield: 178 mg (85%); mp 189–191 C (EtOH); 1H NMR (300
MHz, DMSO-d6): d 1.75 (2H, m,
3J¼ 6.6 Hz, CH2), 1.86 (2H, m, 3J
¼ 6.7 Hz, CH2), 2.53–2.64 (4H, m, (CH2)2C]O), 3.27 (2H, t, 3J ¼
6.8 Hz, CH2N), 3.39 (2H, t,
3J ¼ 6.7 Hz, CH2N), 5.62 (2H, br s,RSC Adv., 2018, 8, 22351–22360 | 22357
RSC Advances PaperNH2), 11.59 (1H, br s, NH);
13C NMR (75 MHz, DMSO-d6): d 22.8
(CH2CH2C]O), 23.9 (CH2), 25.5 (CH2), 31.8 (CH2CH2C]O),
45.2 (CH2N), 45.7 (CH2N), 159.4 (C-3 and C-5), 169.4 (C]O). IR
(KBr) n 3358 (N–H), 3204 (N–H), 1622 (C]O), 1568, 1467, 1397,
1341, 1228, 1062 cm1. Anal. calcd for C9H15N5O: C, 51.66; H,
7.23; N, 33.47. Found: C, 51.58; H, 7.25; N, 33.42.General method for the microwave-assisted synthesis of 3-(5-
amino-1H-1,2,4-triazol-3-yl)propanamides (5j–t)
A mixture of the corresponding N-arylsuccnimide (4a–k) (1
mmol) and aminoguanidine hydrochloride (111 mg, 1 mmol) in
ethanol (1 mL) was irradiated in the 10 mL seamless pressure
vial using microwave system operating at maximal microwave
power up to 300 W at 170 C for 50 min. Aer cooling to the
ambient temperature, 480 mL of KOH solution in ethanol (2.5
M) was added to the vial and the reactionmixture was irradiated
again at 180 C for 15 min. Aer cooling to the ambient
temperature, the reaction mixture was diluted with 15 mL of
water. The precipitated solid was ltered, washed with cold
water and recrystalised from a suitable solvent to give desired
products 5j–t. The reaction was also replicated in an increase
scale of N-arylsuccnimide (4a–k) (10 mmol) and amino-
guanidine hydrochloride (1.11 g, 10 mmol) in ethanol (10 mL).
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(phenyl)propanamide (5j).
Pale brownish solid, yield (1 mmol/10 mmol scale): 135 mg (58%)/
1.30 g (56%), mp 245–246 C (H2O).
1H NMR (300MHz, DMSO-d6):
d 2.65–2.71 (4H, m, (CH2)2C]O), 5.04–5.77 (2H, br s, NH2), 7.01
(1H, t, 3J ¼ 7.4 Hz, H-40), 7.28 (2H, t, 3J ¼ 7.9 Hz, H-30 and H-50),
7.59 (2H, d, 3J ¼ 7.6 Hz, H-20 and H-60), 9.95 (1H, s, NHC]O),
11.57–12.32 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.8
(CH2CH2C]O), 34.3 (CH2CH2C]O), 118.9 (C-20 and C-60), 122.8
(C-40), 128.5 (C-30 and C-50), 139.3 (C-10), 156.7–159.8 (C-3 and C-5),
170.3 (C]O). IR (KBr) n 3464 (N–H), 3298 (N–H), 3164 (N–H), 1649
(C]O), 1596, 1498, 1317, 1258, 1166, 1095 cm1. Anal. calcd for
C11H13N5O: C, 57.13; H, 5.67; N, 30.28. Found: C, 57.05; H, 5.82; N,
30.21.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-uorophenyl)prop-
anamide (5k). White solid, yield (1 mmol/10 mmol scale):
139 mg (56%)/1.51 g (61%), mp 218–220 C (MeOH). 1H NMR
(300 MHz, DMSO-d6): d 2.64–2.70 (4H, m, (CH2)2C]O), 5.00–
5.77 (2H, br s, NH2), 7.12 (2H, dd,
3JHF ¼ 8.9 Hz, 3JHH ¼
8.9 Hz, H-30and H-50), 7.61 (2H, dd, 3JHF ¼ 5.1 Hz, 3JHH ¼
9.1 Hz, H-20 and H-60), 10.00 (1H, s, NHC]O), 11.57–12.33
(1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.7
(CH2CH2C]O), 34.2 (CH2CH2C]O), 115.1 (d,
2JCF ¼
21.6 Hz, C-20 and C-60), 120.6 (d, 3JCF ¼ 7.5 Hz, C-20 and C-60),
135.7 (d, 4JCF ¼ 2.2 Hz, C-10), 157.7 (d, 1JCF ¼ 239.2 Hz, C-10),
156.7 and 159.8 (C-3 and C-5), 170.2 (C]O). IR (KBr) n 3417
(N–H), 3325 (N–H), 3256 (N–H), 1660 (C]O), 1624, 1546,
1404, 1223, 1098, 1068 cm1. Anal. calcd for C11H12FN5O: C,
53.01; H, 4.85; N, 28.10. Found: C, 52.88; H, 4.96; N, 27.92.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(2-chlorophenyl)prop-
anamide (5l). Yellowish solid, yield (1 mmol/10 mmol scale):
112 mg (42%)/1.59 g (60%), mp 179–181 C (MeCN). 1H NMR
(300 MHz, DMSO-d6): d 2.71 (4H, m, (CH2)2C]O), 5.00–5.81
(2H, br s, NH2), 7.16 (1H, dt,
4J ¼ 1.4 Hz, 3J ¼ 7.7 Hz, H-40),22358 | RSC Adv., 2018, 8, 22351–223607.31 (1H, dt, 4J ¼ 1.4 Hz, 3J ¼ 7.7 Hz, H-50), 7.47 (1H, dd, 4J ¼
1.4 Hz, 4J ¼ 8.0 Hz, H-60), 7.74 (1H, d, 3J ¼ 7.7 Hz, H-30), 9.52
(1H, s, NHC]O), 11.60–12.34 (1H, br s, NH). 13C NMR (75
MHz, DMSO-d6): d 24.0 (CH2CH2C]O), 34.0 (CH2CH2C]O),
125.9 (C-40 and C-60), 126.1 (C-50), 127.2 (C-30), 129.3 (C-20),
135.0 (C-10), 156.7 and 159.7 (C-3 and C-5), 170.9 (C]O). IR
(KBr) n 3409 (N–H), 3337 (N–H), 3223 (N–H), 1653 (C]O),
1606, 1539, 1450, 1290, 1101, 1077 cm1. Anal. calcd for
C11H12ClN5O: C, 49.73; H, 4.55; N, 26.36. Found: C, 49.67; H,
4.66; N, 26.22.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(3-chlorophenyl)prop-
anamide (5m). White solid, yield (1 mmol/10 mmol scale):
169 mg (64%)/1.97 g (74%), mp 209–210 C (MeCN). 1H NMR
(300 MHz, DMSO-d6): d 2.68 (4H, m, (CH2)2C]O), 4.99–5.78
(2H, br s, NH2), 7.07 (1H, ddd,
4J ¼ 1.0 Hz, 4J ¼ 2.1 Hz, 3J ¼
7.9 Hz, H-40), 7.31 (1H, t, 3J ¼ 8.1 Hz, H-50), 7.43 (1H, ddd, 4J¼
1.0 Hz, 4J ¼ 1.9 Hz, 3J ¼ 8.3 Hz, H-60), 7.82 (1H, dd, 4J ¼
2.0 Hz, 4J ¼ 2.0 Hz, H-30), 10.15 (1H, s, NHC]O), 11.56–12.33
(1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.6
(CH2CH2C]O), 34.3 (CH2CH2C]O), 117.2 (C-60), 118.3 (C-
20), 122.5 (C-40), 130.2 (C-50), 132.9 (C-30), 140.7 (C-10), 156.8
and 159.9 (C-3 and C-5), 170.8 (C]O). IR (KBr) n 3417 (N–H),
3323 (N–H), 3243 (N–H), 1659 (C]O), 1625, 1597, 1481, 1286,
1097, 1068 cm1. Anal. calcd for C11H12ClN5O: C, 49.73; H,
4.55; N, 26.36. Found: C, 49.62; H, 4.63; N, 26.28.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-chlorophenyl)prop-
anamide (5n). White solid, yield (1 mmol/10 mmol scale):
171 mg (64%)/1.77 g (67%), mp 219–220 C (MeOH). 1H NMR
(300 MHz, DMSO-d6): d 2.67 (4H, m, (CH2)2C]O), 4.98–5.78
(2H, br s, NH2), 7.33 (2H, d,
3J ¼ 8.9 Hz, H-30 and H-50), 7.62
(2H, d, 3J ¼ 8.9 Hz, H-20 and H-60), 10.10 (1H, s, NHC]O),
11.56–12.32 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6):
d 23.7 (CH2CH2C]O), 34.3 (CH2CH2C]O), 120.4 (C-20 and C-
60), 126.3 (C-40), 128.4 (C-30 and C-50), 138.2 (C-10), 156.8 and
159.8 (C-3 and C-5), 170.6 (C]O). IR (KBr) n 3416 (N–H), 3323
(N–H), 3244 (N–H), 1656 (C]O), 1625, 1542, 1480, 1240,
1098, 1068 cm1. Anal. calcd for C11H12ClN5O: C, 49.73; H,
4.55; N, 26.36. Found: C, 49.66; H, 4.61; N, 26.27.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(3-methylphenyl)prop-
anamide (5o). Yellowish solid, yield (1 mmol/10 mmol scale):
113 mg (46%)/1.16 g (47%), mp 202–203 C (MeCN). 1H NMR
(300 MHz, DMSO-d6): d 2.26 (3H, s, CH3), 2.65 (4H, m,
(CH2)2C]O), 4.98–5.77 (2H, br s, NH2), 6.83 (1H, d,
3J ¼
7.5 Hz, H-40), 7.15 (1H, t, 3J ¼ 7.8 Hz, H-50), 7.36 (1H, d, 3J ¼
8.1 Hz, H-60), 7.44 (1H, s, H-20), 9.86 (1H, s, NHC]O), 11.56–
12.32 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 21.1
(CH3), 23.8 (CH2CH2C]O), 34.3 (CH2CH2C]O), 116.1 (C-60),
119.4 (C-20), 123.5 (C-40), 128.4 (C-50), 137.7 (C-30), 138.2 (C-
10), 156.7 and 159.8 (C-3 and C-5), 170.3 (C]O). IR (KBr) n
3417 (N–H), 3323 (N–H), 3250 (N–H), 1660 (C]O), 1623,
1547, 1480, 1210, 1096, 1067 cm1. Anal. calcd for
C12H15N5O: C, 58.76; H, 6.16; N, 28.55. Found: C, 58.69; H,
6.22; N, 28.48.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-methylphenyl)prop-
anamide (5p). White solid, yield (1 mmol/10 mmol scale):
117 mg (48%)/1.05 g (43%), mp 221 C (MeOH). 1H NMR (300
MHz, DMSO-d6): d 2.24 (3H, s, CH3), 2.63–2.70 (4H, m,This journal is © The Royal Society of Chemistry 2018
Paper RSC Advances(CH2)2C]O), 5.03–5.77 (2H, br s, NH2), 7.08 (2H, d,
3J ¼
8.2 Hz, H-30 and H-50), 7.47 (2H, d, 3J ¼ 8.4 Hz, H-20 and H-60),
9.86 (1H, s, NHC]O), 11.56–12.31 (1H, br s, NH). 13C NMR
(75 MHz, DMSO-d6): d 20.3 (CH3), 23.9 (CH2CH2C]O), 34.2
(CH2CH2C]O), 118.9 (C-20 and C-60), 128.9 (C-30 and C-50),
131.6 (C-40), 136.8 (C-10), 156.6 and 159.8 (C-3 and C-5), 170.1
(C]O). IR (KBr) n 3306 (N–H), 3192 (N–H), 3130 (N–H), 1663
(C]O), 1608, 1553, 1406, 1236, 1110, 1060 cm1. Anal. calcd
for C12H15N5O: C, 58.76; H, 6.16; N, 28.55. Found: C, 58.68; H,
6.20; N, 28.48.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-isopropylphenyl)prop-
anamide (5q). White solid, yield (1 mmol/10 mmol scale):
162 mg (59%)/1.86 g (68%), mp 187–188 C (MeCN). 1H NMR
(300 MHz, DMSO-d6): d 1.17 (6H, d,
3J ¼ 6.9 Hz, (CH3)2CH),
2.64–2.67 (4H, m, (CH2)2C]O), 2.82 (1H, m,
3J ¼ 6.9 Hz,
(CH3)2CH), 4.98–5.78 (2H, br s, NH2), 7.14 (2H, d,
3J¼ 8.5 Hz, H-
30 and H-50), 7.49 (2H, d, 3J ¼ 8.5 Hz, H-20 and H-60), 9.86 (1H, s,
NHC]O), 11.56–12.32 (1H, br s, NH). 13C NMR (75 MHz,
DMSO-d6): d 23.9 ((CH3)2CH), 23.9 (CH2CH2C]O), 32.7
((CH3)2CH), 34.4 (CH2CH2C]O), 119.0 (C-20 and C-60), 126.2 (C-
30 and C-50), 137.0 (C-10), 142.8 (C-40), 156.6 and 159.8 (C-3 and
C-5), 170.2 (C]O). IR (KBr) n 3429 (N–H), 3306 (N–H), 3243 (N–
H), 1651 (C]O), 1594, 1532, 1414, 1251, 1093, 1065 cm1. Anal.
calcd for C14H19N5O: C, 61.52; H, 7.01; N, 25.62. Found: C,
61.40; H, 7.08; N, 25.54.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(3-methoxyphenyl)prop-
anamide (5r). Brownish solid, yield (1 mmol/10 mmol scale):
67 mg (26%)/812 mg (31%), mp 174–175 C (MeCN). 1H NMR
(300 MHz, DMSO-d6): d 2.65–2.70 (4H, m, (CH2)2C]O), 3.34
(3H, s, OCH3), 5.07–5.76 (2H, br s, NH2), 6.60 (1H, ddd,
4J ¼
1.1 Hz, 4J ¼ 2.5 Hz, 3J ¼ 8.0 Hz, H-60), 7.11 (1H, ddd, 4J ¼ 1.5 Hz,
4J ¼ 1.5 Hz, 3J¼ 8.3 Hz, H-40), 7.18 (1H, t, 3J ¼ 8.0 Hz, H-50), 7.32
(1H, dd, 4J ¼ 2.0 Hz, 4J ¼ 2.0 Hz, H-20), 9.94 (1H, s, NHC]O),
11.58–12.30 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.6
(CH2CH2C]O), 34.3 (CH2CH2C]O), 54.8 (OCH3), 104.7 (C-20),
108.3 (C-40), 111.2 (C-60), 129.3 (C-50), 140.4 (C-10), 156.8 and
159.4 (C-3 and C-5), 159.4 (C-30), 170.4 (C]O). IR (KBr) n 3438
(N–H), 3304 (N–H), 3223 (N–H), 1670 (C]O), 1612, 1548, 1478,
1211, 1074, 1045 cm1. Anal. calcd for C12H15N5O2: C, 55.16; H,
5.79; N, 26.80. Found: C, 55.04; H, 5.86; N, 26.68.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-methoxyphenyl)prop-
anamide (5s). White solid, yield (1 mmol/10 mmol scale):
131 mg (50%)/1.19 g (46%), mp 221–222 C (MeOH). 1H NMR
(300 MHz, DMSO-d6): d 2.62–2.67 (4H, m, (CH2)2C]O), 3.71
(3H, s, OCH3), 4.98–5.77 (2H, br s, NH2), 6.85 (2H, d,
3J¼ 9.1 Hz,
H-30 and H-50), 7.49 (2H, d, 3J ¼ 9.0 Hz, H-20 and H-60), 9.80
(1H, s, NHC]O), 11.55–12.31 (1H, br s, NH). 13C NMR (75 MHz,
DMSO-d6): d 23.9 (CH2CH2C]O), 33.7 (CH2CH2C]O), 55.0
(OCH3), 113.7 (C-30 and C-50), 120.4 (C-20 and C-60),132.5 (C-10),
154.9 (C-40), 156.6 and 159.8 (C-3 and C-5), 169.8 (C]O). IR
(KBr) n 3416 (N–H), 3295 (N–H), 3135 (N–H), 1652 (C]O), 1548,
1515, 1407, 1249, 1067, 1029 cm1. Anal. calcd for C12H15N5O2:
C, 55.16; H, 5.79; N, 26.80. Found: C, 55.05; H, 5.82; N, 26.73.
3-(5-Amino-1H-1,2,4-triazol-3-yl)-N-(4-acetamidophenyl)prop-
anamide (5t). Light grey solid, yield (1 mmol/10 mmol scale):
110 mg (38%)/1.28 g (44%), mp 267–269 C (H2O).
1H NMR (300
MHz, DMSO-d6): d 2.01 (3H, s, CH3C]O), 2.63–2.68 (4H, m,This journal is © The Royal Society of Chemistry 2018(CH2)2C]O), 4.97–5.77 (2H, br s, NH2), 7.44–7.51 (4H, m, H-20,
H-30, H-50, H-60), 9.82 (1H, s, NHC]O), 9.88 (1H, s, NHC]O),
11.55–12.32 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6): d 23.8
(CH2CH2C]O), 33.7 (CH2CH2C]O), 119.2 (C-20, C-30, C-50 and
C-60), 134.5 (C-40), 134.5 (C-10), 156.7 and 159.8 (C-3 and C-5),
167.8 (C]OCH3), 170.0 (C]O). IR (KBr) n 3463 (N–H), 3306
(N–H), 3117 (N–H), 3030 (N–H), 1662 (C]O), 1617, 1533, 1408,
1277, 1120, 1058 cm1. Anal. calcd for C13H16N6O2: C, 54.16; H,
5.59; N, 29.15. Found: C, 54.02; H, 5.64; N, 29.00.X-Ray crystallographic analysis
Intensity data for 5j were measured for a colourless crystal (0.09
 0.13  0.24 mm) at 100 K on an Rigaku/Oxford Diﬀraction
XtaLAB Synergy diﬀractometer (Dualex, AtlasS2) tted with
CuKa radiation (l ¼ 1.54178 A˚) so that qmax ¼ 67.1. Data
reduction and Gaussian absorption corrections were by stan-
dard methods.21 The structure was solved by direct-methods22
and rened on F2 (ref. 23) with anisotropic displacement
parameters, C-bound H atoms included in the riding model
approximation and N-bound H atoms rened with N–H ¼ 0.88–
0.91  0.01 A˚. A weighting scheme of the form w ¼ 1/[s2(Fo2) +
(0.043P)2 + 0.479P] where P¼ (Fo2 + 2Fc2)/3) was introduced. The
molecular structure diagram showing 70% probability
displacement ellipsoids was generated by ORTEP for Windows24
and the packing diagrams with DIAMOND.25 Additional data
analysis was made with PLATON.26 In order to conrm the
location of the acidic-H atoms, an unrestrained renement was
performed which yielded N–H bond lengths in the range 0.84(2)
to 0.898(18) A˚, thereby, conforming the original assignment.
Crystal data for 3-(5-amino-1H-1,2,4-triazol-3-yl)-N-(phenyl)
propanamide (5j). M ¼ 231.26, monoclinic, P21/n, a ¼
8.58760(10), b ¼ 9.09790(10), c ¼ 14.20640(10) A˚, b ¼
100.8930(10), V ¼ 1089.934(19) A˚3, Z ¼ 4, Dx ¼ 1.409 g cm3,
F(000) ¼ 488, m ¼ 0.795 mm1, no. rens meas. ¼ 25 310, no.
unique rens ¼ 1939 (Rint ¼ 0.028), no. rens with I $ 2s(I) ¼
1882, no. parameters ¼ 166, R (obs. data) ¼ 0.032, wR2 (all data)
¼ 0.081. CCDC deposition number: 1844791.Conﬂicts of interest
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